Does Ozempic Protect Your Heart? What a 17,000-Person Trial Actually Found
A trial of 17,604 people found that Ozempic reduced heart attacks, strokes, and cardiovascular deaths by 20%. But the finding that changed everything was that this protection existed whether people lost a lot of weight or almost none. These medications do something to the heart that has nothing to do with the number on the scale.
GLP-1 medications reduce major cardiovascular events by 20% in people with established heart disease — without diabetes. That is the SELECT trial finding published in the New England Journal of Medicine. The critical detail, confirmed by a 2025 Lancet prespecified analysis of the same trial, is that the cardiovascular benefit was independent of weight loss magnitude. People who lost very little weight showed similar cardiovascular protection to those who lost significantly more. This means GLP-1 medications have direct cardioprotective mechanisms that go beyond their effect on body weight.
Part of the GLP-1 Optimization system
This article is part of the GLP-1 Optimization hub — the complete evidence-based framework for getting the most from Ozempic, Wegovy, Mounjaro, and Zepbound. The hub connects protein strategy, side effect management, cardiovascular health, bone protection, and the maintenance phase in one structured system.
The SELECT Trial Numbers
The 20% relative risk reduction translates to a 1.5% absolute risk reduction — major cardiovascular events occurred in 6.5% of semaglutide participants versus 8.0% of placebo participants over a median follow-up of 33 months. The number needed to treat to prevent one cardiovascular event is approximately 67 people over that period.
To put that in context: statins, which are considered one of the most effective cardiovascular preventive therapies ever developed, reduce major cardiovascular events by approximately 25 to 35% in high-risk populations. A 20% reduction from a medication that was originally developed for blood sugar control and weight management is a landmark finding that has fundamentally changed how cardiovascular medicine views this drug class.
The SELECT Trial Explained
SELECT stands for Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity. It was a randomised controlled trial conducted across 41 countries with 17,604 participants. The specific population was adults with a BMI of 27 or above, established cardiovascular disease defined as prior heart attack, stroke, or peripheral arterial disease, and no diabetes.
That last criterion — no diabetes — is what makes SELECT historically significant. Previous cardiovascular outcomes trials for GLP-1 medications had been conducted in people with type 2 diabetes, where the cardiovascular benefits were partly explained by improved blood sugar control. SELECT was the first trial to demonstrate cardiovascular protection from a GLP-1 medication in people without diabetes, where improved glycaemic control could not explain the benefit.
Participants received either weekly subcutaneous semaglutide 2.4mg or placebo, in addition to standard care for secondary cardiovascular prevention. The primary outcome was a composite of cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke.
A prespecified analysis published in The Lancet in October 2025 examined whether the cardiovascular benefit in SELECT depended on how much weight participants lost. It did not. The 20% reduction in cardiovascular events was consistent across all baseline body weight and waist circumference categories, and the benefit did not correlate with the magnitude of weight lost. The authors concluded that semaglutide should be reconceptualised as a disease-modifying treatment rather than solely a weight loss or glycaemic control medication. Prescribing restrictions based on BMI thresholds or weight loss targets may not be appropriate for people who need cardiovascular protection.
The Key Cardiovascular Trials
17,604 adults with established cardiovascular disease, overweight or obesity, without diabetes. Randomised to semaglutide 2.4mg weekly or placebo. Median follow-up 33 months across 41 countries. Primary outcome: composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke.
Published in the New England Journal of Medicine November 2023. This was the first rigorous randomised controlled trial to demonstrate that a weight management therapy reduces the risk of cardiovascular events — establishing overweight and obesity as modifiable cardiovascular risk factors in the same way high blood pressure and high cholesterol are modifiable risk factors.
616 adults with heart failure with preserved ejection fraction (HFpEF) and obesity, without diabetes. Semaglutide 2.4mg versus placebo for 52 weeks. HFpEF is a form of heart failure where the heart muscle contracts normally but the ventricles are stiff — it affects around 50% of all heart failure patients and has historically had very limited treatment options.
Semaglutide produced significant improvements in symptoms and physical limitations as measured by the Kansas City Cardiomyopathy Questionnaire. Exercise capacity improved and C-reactive protein — a marker of systemic inflammation — decreased significantly. A companion trial (STEP-HFpEF-DM) replicated these findings in people with HFpEF and diabetes.
731 adults with HFpEF and obesity. Tirzepatide versus placebo for 52 weeks. The SUMMIT trial was the first cardiovascular outcomes trial for tirzepatide in heart failure and produced results that exceeded those of semaglutide in the same indication — likely reflecting tirzepatide’s dual GLP-1 and GIP receptor mechanism and its greater weight reduction.
SUMMIT showed significant reduction in cardiovascular death and worsening heart failure events, alongside improvements in symptoms and quality of life. Imaging substudy data showed reduced left ventricular mass and reduced paracardiac fat. The SUMMIT results contributed to tirzepatide receiving FDA approval for heart failure with preserved ejection fraction in 2025.
Prior to SELECT, the SUSTAIN-6 trial (semaglutide in type 2 diabetes, 3,297 participants) and LEADER trial (liraglutide in type 2 diabetes, 9,340 participants) had already shown cardiovascular benefits in people with diabetes. SUSTAIN-6 showed a 26% reduction in MACE. LEADER showed a 13% reduction in cardiovascular death. These trials established the cardiovascular safety and benefit profile of GLP-1 medications but left open the question of whether benefits existed independent of glycaemic control — the question SELECT definitively answered.
Why GLP-1 Medications Protect the Heart
The mechanisms behind cardiovascular protection from GLP-1 medications are now better understood following the SELECT prespecified analyses and the mechanistic work from STEP-HFpEF and SUMMIT. The effects operate through two categories: weight-dependent effects that follow from the weight loss these medications produce, and weight-independent effects that arise from direct GLP-1 receptor activation in cardiac and vascular tissue.
Visceral Fat Reduction
Visceral fat — the fat stored around internal organs including the heart — is metabolically active and produces pro-inflammatory cytokines that damage cardiac tissue and blood vessel walls. Reductions in visceral fat reduce this inflammatory load directly. GLP-1 medications tend to preferentially reduce visceral fat over subcutaneous fat, which amplifies the cardiovascular benefit relative to total weight lost.
Blood Pressure Reduction
Tirzepatide reduces systolic blood pressure by 4 to 6 mmHg on average. Semaglutide produces similar reductions. Even modest blood pressure reductions have significant cardiovascular risk implications — each 5 mmHg reduction in systolic blood pressure reduces the risk of major cardiovascular events by approximately 10%. This effect is partly weight-mediated and partly through direct vascular mechanisms.
Improved Insulin Sensitivity
Insulin resistance is a major driver of cardiovascular risk independent of blood sugar levels. It promotes atherosclerosis, endothelial dysfunction, and systemic inflammation. GLP-1 medications improve insulin sensitivity significantly through both weight loss and direct receptor-mediated effects, reducing this cardiovascular risk pathway even in people without diabetes.
Direct Cardiac GLP-1 Receptor Activation
GLP-1 receptors are expressed directly on cardiac muscle cells. GLP-1 receptor activation in the heart improves calcium handling in cardiomyocytes, reduces oxidative stress, and has anti-apoptotic effects that protect cardiac cells from ischaemic damage. This direct cardioprotective mechanism is weight-independent and contributes to the cardiovascular benefit seen even in participants who lost minimal weight in the SELECT trial.
Systemic Anti-Inflammatory Effects
GLP-1 receptor activation reduces the production of pro-inflammatory cytokines including TNF-alpha, IL-6, and CRP. The STEP-HFpEF trials showed significant reductions in C-reactive protein independent of weight loss — confirming that the anti-inflammatory effect is not simply a downstream consequence of losing fat. Chronic systemic inflammation is a major driver of atherosclerosis and cardiovascular risk. Reducing it directly provides independent cardiovascular protection.
Endothelial Protection
The endothelium — the inner lining of blood vessels — plays a critical role in cardiovascular health. GLP-1 receptor activation improves endothelial function, enhances nitric oxide production which promotes vasodilation, and has anti-atherosclerotic effects that slow the development of arterial plaques. These vascular protective effects operate independently of weight loss and contribute to the cardiovascular benefit across the full spectrum of weight loss responses.
What This Means If You Are on These Medications
Most people starting Ozempic, Wegovy, Mounjaro, or Zepbound are focused on weight loss. The cardiovascular data from SELECT and SUMMIT expands that picture significantly.
For people with existing cardiovascular disease, these medications offer meaningful protection against further cardiovascular events beyond what standard care provides. The SELECT data suggests this protection exists whether you are a strong weight loss responder or a minimal responder to the medication.
For people without existing cardiovascular disease, the metabolic improvements from GLP-1 therapy — reduced visceral fat, lower blood pressure, improved insulin sensitivity, reduced systemic inflammation — represent meaningful reductions in future cardiovascular risk that extend well beyond the cosmetic outcome of weight loss.
The 73% reduction in incident diabetes seen as a secondary outcome in SELECT is particularly striking. For people with overweight or obesity who are not yet diabetic, preventing the development of type 2 diabetes represents a significant reduction in downstream cardiovascular risk that compounds over decades.
The cardiovascular benefit from GLP-1 medications is amplified by the nutritional strategy used during treatment. Visceral fat reduction is maximised when protein intake is high enough to preserve lean mass — because lean mass preservation maintains resting metabolic rate which drives deeper into visceral fat stores over time. Resistance training adds a further independent cardiovascular benefit through improved cardiac function, blood pressure, and metabolic health. The GLP-1 Protein Calculator provides your personalised protein target and the building muscle on GLP-1 guide covers the training protocol that complements the cardiovascular benefits of the medication.
Cardiovascular Outcomes — At a Glance
| Trial | Medication | Population | Key cardiovascular finding |
|---|---|---|---|
| SELECT | Semaglutide 2.4mg | 17,604 adults with CVD, no diabetes | 20% reduction in MACE. Benefit independent of weight loss. |
| STEP-HFpEF | Semaglutide 2.4mg | 616 adults with HFpEF and obesity | Significant improvement in symptoms and CRP reduction independent of weight loss. |
| SUMMIT | Tirzepatide 15mg | 731 adults with HFpEF and obesity | Significant reduction in cardiovascular death and worsening heart failure. |
| SUSTAIN-6 | Semaglutide 0.5/1mg | 3,297 adults with type 2 diabetes | 26% reduction in MACE in diabetes population. |
| LEADER | Liraglutide 1.8mg | 9,340 adults with type 2 diabetes | 13% reduction in cardiovascular death in diabetes population. |
The complete GLP-1 framework
The GLP-1 Optimization hub connects all the evidence-based guides that support outcomes during GLP-1 therapy. The bone loss guide covers the skeletal risk that accompanies rapid weight loss. The maintenance phase guide covers what happens to cardiovascular risk when the medication is stopped and the clinical data on continued versus discontinued treatment. The GLP-1 Side Effects hub connects all articles on managing the physical changes of treatment. The GLP-1 Symptom Checker analyses your full symptom pattern and generates a personalised action plan.
Frequently Asked Questions
Yes. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in 17,604 people with established cardiovascular disease and no diabetes. The benefit was independent of how much weight participants lost — people who lost minimal weight showed similar cardiovascular protection. GLP-1 medications are now considered disease-modifying treatments for cardiovascular risk, not just weight loss medications.
SELECT was a randomised controlled trial of 17,604 adults with established cardiovascular disease, overweight or obesity, and no diabetes. Semaglutide 2.4mg weekly reduced major cardiovascular events by 20% versus placebo over a median 33-month follow-up. Secondary outcomes showed a 73% reduction in incident diabetes and a 22% reduction in kidney disease outcomes. A 2025 Lancet prespecified analysis confirmed the cardiovascular benefit was independent of weight loss magnitude.
Yes. Non-fatal heart attacks were significantly reduced in SELECT — part of the composite primary outcome that showed a 20% overall reduction. The absolute risk reduction of 1.5% over 33 months translates to approximately 67 people needing to be treated to prevent one major cardiovascular event. This is clinically meaningful and comparable to the benefit seen with statins in high-risk populations.
Yes. Tirzepatide demonstrated significant cardiovascular benefits in the SUMMIT trial, reducing cardiovascular death and worsening heart failure in people with heart failure and obesity. Tirzepatide also reduces multiple cardiovascular risk factors simultaneously including blood pressure, visceral fat, systemic inflammation, and insulin resistance. A dedicated cardiovascular outcomes trial equivalent to SELECT is ongoing for tirzepatide in people without diabetes.
GLP-1 medications protect the heart through weight-dependent effects including visceral fat reduction, blood pressure lowering, and improved insulin sensitivity, and weight-independent effects including direct GLP-1 receptor activation on cardiac tissue, systemic anti-inflammatory effects reducing CRP and cytokine production, and endothelial protection improving blood vessel function. The discovery that cardiovascular benefit in SELECT did not depend on weight loss magnitude confirmed these direct cardioprotective mechanisms are clinically significant.
Research and References
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221–2232. The SELECT trial primary publication. pubmed.ncbi.nlm.nih.gov | nejm.org
- Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. 2025;406:2257–2268. Confirms benefit independent of weight loss magnitude. thelancet.com
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024;30:2049–2057. Four-year weight loss and anthropometric outcomes. nature.com
- Kosiborod MN, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. STEP-HFpEF trial. New England Journal of Medicine. 2023;389(12):1069–1084. pubmed.ncbi.nlm.nih.gov
- Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. SUMMIT trial. New England Journal of Medicine. 2025;392(5):427–437. pubmed.ncbi.nlm.nih.gov
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. SUSTAIN-6 trial. New England Journal of Medicine. 2016;375(19):1834–1844. pubmed.ncbi.nlm.nih.gov
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. LEADER trial. New England Journal of Medicine. 2016;375(4):311–322. pubmed.ncbi.nlm.nih.gov
- Abdul-Hafez et al. Tirzepatide and cardiovascular outcomes: mechanisms, efficacy and implications for heart failure management. Endocrinology, Diabetes and Metabolism. 2026. onlinelibrary.wiley.com
- Cleveland Clinic. International clinical trial finds semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity without diabetes. November 2023. clevelandclinic.org